Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party—EBMT


Autologous hematopoietic stem cell transplantation (ASCT) is curative for a proportion of patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL). However, there is a small group of patients with high-risk of relapse after ASCT that might benefit from other approaches. We conducted a retrospective analysis on 126 patients treated with tandem ASCT-reduced intensity conditioning (RIC)-allogeneic-SCT and reported to the EBMT registry to analyze the efficacy and safety of this approach. Patients were included if they had received an ASCT followed by a planned RIC-SCT in <6 months without relapse between the procedures. The median time between diagnosis and ASCT was 16 months (2–174). The median number of lines prior to ASCT was two (33% of the patients received >3 lines). Forty-one percent were transplanted with active disease. The median follow-up was 44 months (6–130). Three-year-progression-free survival (PFS), overall survival (OS), incidence of relapse (IR), and non-relapse mortality (NRM) after the tandem were 53% (45–64), 73% (65–81), 34% (24–42), and 13% (8–21), respectively. This is the largest series analyzing the efficacy and safety of a tandem approach in R/R HL. The low NRM and IR with promising PFS and OS suggest that this might be an effective procedure for a high-risk population.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: CI of relapse, NRM, PFS and OS of all series.
Fig. 2: PFS and OS according to the interval from diagnosis to ASCT.
Fig. 3: PFS and OS according to number of lines prior to ASCT.
Fig. 4: CI of acute and chronic GVHD.


  1. 1.

    Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065–71.

    CAS  Article  Google Scholar 

  2. 2.

    Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong T-C, Prince HM, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30:2197–203.

    CAS  Article  Google Scholar 

  3. 3.

    Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica. 2013;98:611–4.

    CAS  Article  Google Scholar 

  4. 4.

    Corazzelli G, Angrilli F, D’Arco A, Ferrara F, Musto P, Guarini A, et al. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol. 2013;160:207–15.

    CAS  Article  Google Scholar 

  5. 5.

    Anastasia A, Carlo-Stella C, Corradini P, Salvi F, Rusconi C, Pulsoni A, et al. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. Br J Haematol. 2014;166:140–2.

    CAS  Article  Google Scholar 

  6. 6.

    Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–9.

    CAS  Article  Google Scholar 

  7. 7.

    Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010;115:3671–7.

    CAS  Article  Google Scholar 

  8. 8.

    Crocchiolo R, Castagna L, Fürst S, El-Cheikh J, Faucher C, Oudin C, et al. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2013;48:249–52.

    CAS  Article  Google Scholar 

  9. 9.

    Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Annals of oncology: official journal of the European Society for. Med Oncol. 2019;30:612–20.

    CAS  Google Scholar 

  10. 10.

    Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853–62.

    CAS  Article  Google Scholar 

  11. 11.

    Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639–42.

    CAS  Article  Google Scholar 

  12. 12.

    Lazarus HM, Loberiza FR, Zhang MJ, Armitage JO, Ballen KK, Bashey A, et al. Autotransplants for Hodgkin’s disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant. 2001;27:387–96.

    CAS  Article  Google Scholar 

  13. 13.

    Arai S, Fanale M, DeVos S, Engert A, Illidge T, Borchmann P, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54:2531–3.

    Article  Google Scholar 

  14. 14.

    Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol. 2000;18:3918–24.

    CAS  Article  Google Scholar 

  15. 15.

    Castagna L, Crocchiolo R, Giordano L, Bramanti S, Carlo-Stella C, Sarina B, et al. High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. Bone Marrow Transplant. 2015;50:499–504.

    CAS  Article  Google Scholar 

  16. 16.

    Mariotti J, Bramanti S, Devillier R, Furst S, El Cheikh J, Sarina B, et al. Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma. Bone Marrow Transplant. 2018;53:366–70.

    CAS  Article  Google Scholar 

  17. 17.

    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

    Article  Google Scholar 

  18. 18.

    Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.

    Article  Google Scholar 

  19. 19.

    Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.

    CAS  Article  Google Scholar 

  20. 20.

    Terwey TH, Vega-Ruiz A, Hemmati PG, Martus P, Dietz E, le Coutre P, et al. NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemia. Leukemia. 2012;26:536–42.

    CAS  Article  Google Scholar 

  21. 21.

    Morschhauser F, Brice P, Fermé C, Diviné M, Salles G, Bouabdallah R, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin’s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol. 2008;26:5980–7.

    Article  Google Scholar 

  22. 22.

    Deau B, Amorim S, Perrot A, Quittet P, Cornillon J, Chaoui D, et al. Tandem haematopoietic stem cell transplantation for high risk relapsed/refractory Hodgkin lymphoma: a LYSA study. Br J Haematol. 2018;181:341–9.

    Article  Google Scholar 

  23. 23.

    Chen R, Palmer JM, Thomas SH, Tsai N-C, Farol L, Nademanee A, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012;119:6379–81.

    CAS  Article  Google Scholar 

  24. 24.

    Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase ii checkmate 205 trial. J Clin Oncol. 2018;36:1428–39.

    CAS  Article  Google Scholar 

  25. 25.

    Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378:331–44.

    CAS  Article  Google Scholar 

  26. 26.

    Armand P, Chen Y-B, Redd RA, Joyce RM, Bsat J, Jeter E, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019;134:22–9.

    CAS  Article  Google Scholar 

  27. 27.

    LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132:40–8.

    CAS  Article  Google Scholar 

  28. 28.

    Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, et al. Maintenance therapies for hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. JAMA Oncol. 2019;5:715–22.

    Article  Google Scholar 

Download references


LB and AS performed the research. LB, HF, IK, DB, NF, LC, EF, PC, NM, PB, ED, MG, PC, MH, MM, AT, DC, and SN contributed to clinical data. LB, AB, SM, and AS contributed to the analysis and data interpretation. AB served as the statistician. All authors contributed to review, provided their comments on this manuscript and approval the final version.

Author information




Corresponding author

Correspondence to Leyre Bento.

Ethics declarations

Conflict of interest

Authors do not report any conflict of interest in the present manuscript.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This study has been presented as an oral presentation at 46st Annual Meeting of the European Society for Blood and Marrow Transplantation on the 26th March 2019 and at 24th European Haematology Association Congress on the 16th June 2019.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bento, L., Boumendil, A., Finel, H. et al. Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party—EBMT. Bone Marrow Transplant (2020). https://doi.org/10.1038/s41409-020-01075-y

Download citation